drugset
drugset / Trial / NCT00070525

Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma

NCT00070525 ↗

Phase 2 Completed 90 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well tipifarnib works in treating young patients with recurrent or progressive high-grade glioma, medulloblastoma, primitive neuroectodermal tumor, or brain stem glioma. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

Timeline

Start
2003-11
Primary completion
2006-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject tipifarnib Small molecule — Oral

Indications

childhood brain stem glioma childhood cerebellar astrocytic neoplasm childhood cerebral astrocytoma childhood medulloblastoma childhood oligodendroglioma optic pathway glioma supratentorial primitive neuroectodermal tumor